Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc. (NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences, Inc. (NASDAQ: GILD) is already one of the most profitable companies on the planet, but a readout expected in the near future could be a big step toward addressing one of the largest unmet needs in medicine. Here’s a rundown of upcoming events that will alter perceptions of their candidates’ potential in the days and weeks ahead.